[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351533-105":59,"doc-detail-351533-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","a-systematic-review-and-meta-analysis-of-the-impact-of-tumour-mutation-burden-on-survival-outcomes-in-solid-tumours","A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid Tumours","","Tumour mutation burden (TMB) is an emerging pan-cancer biomarker for immune checkpoint inhibitor (ICI) response, yet conclusions differ because studies use varying methods and cut-off thresholds. This systematic review and meta-analysis evaluates how TMB relates to overall survival (OS) and progression-free survival (PFS) across solid tumours, including ICI-treated and non-ICI-treated cohorts. It synthesizes hazard ratios from studies (2010–2024), applies quality and bias assessments, and tests robustness using leave-one-out analysis.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-systematic-review-and-meta-analysis-of-the-impact-of-tumour-mutation-burden-on-survival-outcomes-in-solid-tumours/351533/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-systematic-review-and-meta-analysis-of-the-impact-of-tumour-mutation-burden-on-survival-outcomes-in-solid-tumours/351533.png","ImageObject",300,407,{"name":92,"@type":93},"วิน","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What question does the study address about tumour mutation burden?","Question",{"text":113,"@type":114},"It assesses the impact of tumour mutation burden (TMB) on overall survival (OS) and progression-free survival (PFS) across solid tumours, separately considering ICI-treated and non-ICI-treated cohorts.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How did the authors define high and low TMB and ultra-high TMB?",{"text":118,"@type":114},"High and low TMB were defined by study-specific cut-offs, while ultra-high TMB was defined as the top 20% of cohort-specific values.",{"name":120,"@type":111,"acceptedAnswer":121},"What are the main findings regarding TMB and survival outcomes?",{"text":122,"@type":114},"High TMB was significantly associated with improved OS and PFS, with benefits strongest in ICI-treated patients and in selected cancers. Associations were weaker and inconsistent in non-ICI-treated cohorts.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},351533,1790599595,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","Cancer Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nA Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid Tumours  \nAijia Meng1  | Alexander Yuile2,3  | Hao-Wen Sim1,4,5,6  | Subotheni Thavaneswaran1,4,5  | Humaira Noor7  | Jacky Yeung8  | Ashish Mehta1  | Joseph Powell1,9  | Ashraf Zaman1,4   \n1Garvan Institute of Medical Research, Sydney, New South Wales, Australia | 2Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia | 3Bill Walsh Translational Cancer Research Laboratory, The Kolling Institute, Sydney, New South Wales, Australia | 4School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales (UNSW), Sydney, New South Wales, Australia | 5The Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia | 6NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia | 7Department of Medicine, Stanford Center for Biomedical Informatics Research (BMIR), Stanford University, Stanford, California, USA | 8Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut, USA | 9UNSW Cellular Genomics Futures Institute, University of New South Wales (UNSW), Sydney, New South Wales, Australia  \nCorrespondence: Ashraf Zaman ([ashraf.zaman@unsw.edu.au](ashraf.zaman@unsw.edu.au))  \nReceived: 14 February 2025 | Revised: 16 April 2026 | Accepted: 18 April 2026  \nKeywords: immunotherapy | meta-analysis | overall survival | progression-free survival | tumour mutation burden  \nABSTRACT  \nBackground: Tumour mutation burden (TMB) is an emerging pan-cancer biomarker with predictive value for immune checkpoint inhibitor (ICI) outcomes, yet evidence is inconsistent due to methodological variability and cut-off thresholds. This systematic review and meta-analysis evaluated the impact of TMB on overall survival (OS) and progression-free survival (PFS) across solid tumours in ICI-treated cohorts and its predictive relevance in non-ICI-treated cohorts.  \nMethods: Following PRISMA 2020 guidelines, we searched PubMed, Scopus, ScienceDirect and Cochrane for studies published between 2010 and 2024 reporting hazard ratios (HRs) and 95% confidence intervals (CIs) for OS and PFS in high-versus low-TMB cohorts. High and low TMB were defined by study-specific cut-offs, and ultra-high TMB was defined as the top 20% of cohortspecific values. Study quality was assessed with the Newcastle-Ottawa Scale; heterogeneity with I2; publication bias with funnel plots/Egger's test; and robustness by leave-one-out analysis.  \nResults: 5278 patients across 28 studies were analysed. High TMB, defined by cohort-specific cut-offs, was significantly associated with improved OS and PFS, particularly in non-small cell lung cancer (OS: HR = 0.56), selected gastrointestinal cancers (OS: HR = 0.36), and advanced/recurrent tumours (OS: HR = 0.52). Benefits were greatest in ICI-treated patients, especially with combined anti-PD-L1/PD-1 and anti-CTLA-4 therapy (OS: HR = 0.47; PFS: HR = 0.50) . Chemotherapy-treated cohorts also showed better outcomes, but less consistently (OS: HR = 0.60; PFS: HR = 0.55) . Ultra-high TMB had better OS than the universal 10 mut/ Mb cut-off (HR = 0.44 vs. 0.58). Non-beneficial associations were observed in glioma and penile squamous cell carcinoma, highlighting disease-specific variability. Sequencing platforms and cut-off definitions remained sources of heterogeneity. Conclusion: TMB demonstrates prognostic relevance and predictive utility in a histology- and treatment-context-dependent manner, with the most consistent associations in selected ICI-treated tumours. Associations in non-ICI-treated cohorts were weaker and inconsistent, indicating putative predictive value. Standardising TMB assessment and refining relevant thresholds are essential for optimising its role in precision oncology.  \nTrial Registration: PROSPERO Registration Number: CRD42024608809  \nThi","cbCaihNuCOFEwEwd","https://ap.wps.com/l/cbCaihNuCOFEwEwd","pdf",11197808,21,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Rationale for ICIs and variability in response\n## TMB as a biomarker for ICI efficacy","[{\"question\":\"What question does the study address about tumour mutation burden?\",\"answer\":\"It assesses the impact of tumour mutation burden (TMB) on overall survival (OS) and progression-free survival (PFS) across solid tumours, separately considering ICI-treated and non-ICI-treated cohorts.\"},{\"question\":\"How did the authors define high and low TMB and ultra-high TMB?\",\"answer\":\"High and low TMB were defined by study-specific cut-offs, while ultra-high TMB was defined as the top 20% of cohort-specific values.\"},{\"question\":\"What are the main findings regarding TMB and survival outcomes?\",\"answer\":\"High TMB was significantly associated with improved OS and PFS, with benefits strongest in ICI-treated patients and in selected cancers. Associations were weaker and inconsistent in non-ICI-treated cohorts.\"}]","A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid Tumours | PDF",1790094610,53,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2dcacaea0c48100de6c39d37e4970c54.webp",983,1291,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e39edd17353e86b6ef0af0614c7b88df.webp",982,1290,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce33c7bae070cebf745a334285f7fa01.webp",981,1289,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f4216a873d04e994c4dc66e9cabf61c.webp",980,1287]